P2-IMU-838-PMS Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis

February 04, 2022
https://clinicaltrials.gov/ct2/show/NCT05054140
Multiple Sclerosis
Principal Investigator: Mirela Cerghet, MD
Multiple Sclerosis
Accepting Participants
313-916-3501